VistaGen Therapeutics
VTGN
106 hedge funds and large institutions have $269M invested in VistaGen Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 29 reducing their positions, and 11 closing their positions.
104% more capital inflows, than outflows
Capital inflows: $25.3M | Capital outflows: $12.4M
31% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 29
2% more funds holding
Funds holding: 104 → 106 (+2)
1.05% more ownership
Funds ownership: 68.13% → 69.18% (+1%)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
93% less call options, than puts
Call options by funds: $73K | Put options by funds: $1.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commodore Capital
New York
|
+$7.25M |
| 2 |
Logos Global Management
San Francisco,
California
|
+$4.34M |
| 3 |
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$3.26M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.62M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM Investors
Solana Beach,
California
|
-$2.31M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$2.18M |
| 3 |
EAM Global Investors
Solana Beach,
California
|
-$1.74M |
| 4 |
Two Sigma Investments
New York
|
-$1.4M |
| 5 |
Millennium Management
New York
|
-$943K |
VTGN Hedge Fund Activity: Q4 2021 in Review
106 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2021, worth a combined $269M — down 25% from $360M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VTGN and 9 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 38 added.
The largest buyer was Commodore Capital, adding an estimated $7.25M. The largest seller was EAM Investors, exiting entirely with an estimated $2.31M sold.
- 106 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2021, up from 104 in Q3 2021.
- Funds reported $269M of VistaGen Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
- 9 funds opened new VistaGen Therapeutics positions in Q4 2021 and 11 closed out, a net change of -2 holders.
- The largest VistaGen Therapeutics buyer in Q4 2021 was Commodore Capital, an estimated $7.25M added.
- The largest VistaGen Therapeutics seller in Q4 2021 was EAM Investors, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2021.